share_log

盘中速览 | 港股三大指数均跌超1%,快手逆势涨超4%

Intraday Overview | The three major Hong Kong stock indices all fell by more than 1%, and Kuaishou bucked the trend and rose more than 4%

Futu News ·  May 23 10:49

Futu News On May 23, the three major Hong Kong stock indices rebounded after an intraday decline. As of press release, the Hang Seng Index fell 1.32%, the Science Index fell 1.08%, and the National Index fell 1.29%.

On the sector side, TechNet stocks showed weak performance. Alibaba and NetEase fell nearly 4%, Tencent Music fell more than 3%, and Xiaomi and Jingdong fell more than 2%.

Auto stocks declined. Zero Sports Auto, Xiaopeng Auto, and Guangzhou Automobile Group fell more than 4%, NIO and Ideal Auto fell nearly 4%, and Geely Auto fell more than 3%.

Mainland property management stocks generally fell. Lingyue Service Group fell nearly 7%, while Kangqiao Yue Life, Evergrande Property, Yongsheng Services, and Ocean Group fell more than 5%.

Airlines stocks declined collectively, with China Southern Airlines falling more than 4%, Beijing Capital Airport shares falling more than 3%, and Cathay Pacific, Eastern Airlines, and Air China falling more than 2%.

The non-ferrous metals sector fell one after another. Ganfeng Lithium fell more than 6%, Lingbao Gold fell 5%, and Zhaojin Mining fell more than 4%.

Chinese brokerage stocks fell more or less, with Guangfa Securities falling nearly 4%, CITIC Construction Investment Securities falling more than 3%, and CICC, Zhongzhou Securities, and China Galaxy falling more than 2%.

In terms of individual stocks,$KUAISHOU-W (01024.HK)$Up more than 4%, Q1 adjusted net profit was 4.388 billion yuan, up 10,347.6% year on year.

$GDS-SW (09698.HK)$It fell nearly 13%, and net revenue for the first quarter increased 9.1% year over year to 2,627 billion yuan.

$HBM HOLDINGS-B (02142.HK)$Buck the trend and surged more than 14%, and its wholly-owned subsidiary Nona Biotech reached a licensing agreement with AstraZeneca for the monoclonal antibody project.

$LAEKNA-B (02105.HK)$The increase was nearly 7%, and the Phase III clinical trial plan for combination therapy for prostate cancer was approved by the FDA.

Editor/Jeffy

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment